NUTX

Rating neutralTentativeAI MemoPost-earnings T+3

Nutex Health

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Prospective IDR-related cost relief • 2026-11-06

Base target: $180 / p=50% prob

Biggest risk

Revenue fell 13.6% in Q2 and same-hospital revenue fell 12.1%. Earnings benefited from unusually favorable contract-services and stock-based-compensation effects, while future savings depend on the IDR process, regulatory conditions, and successful hospital openings.

Invalidation

Break below $125 or thesis failure.

What would change my mind?

The Q2 print showed sharply improved profitability, operating cash flow, hospital visits, and balance-sheet liquidity. Lower IDR-related costs and three planned H2 openings could support earnings durability if collections and execution remain favorable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$180

p=50%

Bull target

$235

p=25%

Bear target

$125

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 profitability and cash-flow inflection
Three planned hospital openings
The Q2 print showed sharply improved profitability, operating cash flow, hospital visits, and balance-sheet liquidity.

BearKey bullets

Execution and ramp risk remain for three planned H2 2026 hospital openings.
Management states that future contract-services expenses may differ significantly from the expected 25%–30% normalized reduction.
Post-earnings analyst revisions, target changes, options data, short interest, employee sentiment, and social coverage are unavailable.

WatchKey bullets

Prospective IDR-related cost relief

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $180 (p=50%)

Target spread vs base: +31% / -31%

Scenario probabilities

Bull Target: $235 (p=25%)Base Target: $180 (p=50%)Bear Target: $125 (p=25%)

Commentary

The post-print tone is constructive but mixed: MarketBeat's Q2 earnings page recorded a $162.07 close on August 7, up 6.67%, while reported revenue declined. The same page displayed consensus EPS and expected-revenue figures but left actual and beat/miss fields unpopulated, so no reliable earnings-surprise comparison or analyst revision signal is available. The company-source results improve the near-term setup, but limited forward visibility supports a monitoring stance.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 profitability and cash-flow inflection
Three planned hospital openings

Scenarios

Bull Target (Scenario probability)

$235 / p=25% prob

Base Target (Scenario probability)

$180 / p=50% prob

Bear Target (Scenario probability)

$125 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-06
Prospective IDR-related cost relief
The HaloMD amendment and lower CMS administrative fee reduced Q2 contract-services expense by $52.3 million; management expects normalized historical contract-services expenses to decline approximately 25%–30% prospectively, subject to regulatory and execution risk [#SEC-8K-2026-08-06].
Prob 70.00% • Move 10.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Q2 profitability and cash-flow inflection
2026-08-06
Nutex reported Q2 net income attributable to the company of $65.8 million, diluted EPS of $9.38, adjusted EBITDA of $90.0 million, operating cash flow of $34.2 million, and hospital visits up 9.6% year over year. Revenue declined 13.6%, partly reflecting prior-year IDR collection effects [#SEC-8K-2026-08-06]. MarketBeat's Q2 earnings page recorded a $162.07 close on August 7, up 6.67%.
Prob 80% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

Three planned hospital openings
2027-08-08
Management expects three new hospitals to open during the second half of 2026, supporting longer-term capacity and volume growth, although opening timing and ramp execution remain uncertain [#SEC-8K-2026-08-06].
Prob 65% • Move 12% • Priced-in 35%

Risks

Execution and ramp risk remain for three planned H2 2026 hospital openings.
Management states that future contract-services expenses may differ significantly from the expected 25%–30% normalized reduction.
Post-earnings analyst revisions, target changes, options data, short interest, employee sentiment, and social coverage are unavailable.
Q2 total revenue declined 13.6% year over year and same-hospital revenue declined 12.1%.
The company depends on IDR execution, with only 50%–60% of claims submitted and collections dependent on award outcomes.

Peers

Symbol	Summary
IRMD	Similar small-cap medical-device exposure, but IRadimed's MRI-compatible device model is not directly comparable to Nutex's micro-hospital and physician-network operations.
BSX	Direct medtech operating reference with much greater scale; useful for procedure-volume and reimbursement context but not a close valuation peer.
EW	Large medical-device peer with hospital exposure, but its structural-heart product portfolio and scale differ materially from Nutex's healthcare-services model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

IRMD

Similar small-cap medical-device exposure, but IRadimed's MRI-compatible device model is not directly comparable to Nutex's micro-hospital and physician-network operations.

BSX

Direct medtech operating reference with much greater scale; useful for procedure-volume and reimbursement context but not a close valuation peer.

Large medical-device peer with hospital exposure, but its structural-heart product portfolio and scale differ materially from Nutex's healthcare-services model.